Evidence map›Paper›PMID 25155019›Full record

ArticleThe Journal of experimental medicine2014

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.

Masashi Shingai, Olivia K Donau, Ronald J Plishka, Alicia Buckler-White, John R Mascola, Gary J Nabel, Martha C Nason, David Montefiori, Brian Moldt, Pascal Poignard and 11 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 245 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
245citing papers in PubMed, 2 pooled it
18.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

245 citing papers in PubMed, 2 syntheses or guidelines pooled it, 328 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Searching for a HIV-1 Cure.Theranostics · 2026
    Review
  20. Article

185 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 4 countries.

Masashi ShingaiLaboratory of Molecular Microbiology, Virology Laboratory, Vaccine Research Center, and Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Olivia K DonauLaboratory of Molecular Microbiology, Virology Laboratory, Vaccine Research Center, and Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Ronald J PlishkaLaboratory of Molecular Microbiology, Virology Laboratory, Vaccine Research Center, and Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Alicia Buckler-WhiteLaboratory of Molecular Microbiology, Virology Laboratory, Vaccine Research Center, and Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
John R MascolaLaboratory of Molecular Microbiology, Virology Laboratory, Vaccine Research Center, and Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Gary J NabelLaboratory of Molecular Microbiology, Virology Laboratory, Vaccine Research Center, and Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Martha C NasonLaboratory of Molecular Microbiology, Virology Laboratory, Vaccine Research Center, and Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
David MontefioriDepartment of Surgery, Duke University Medical Center, Durham, NC 27710.
Brian MoldtDepartment of Immunology and Microbial Science, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037 Department of Immunology and Microbial Science, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037 Department of Immunology and Microbial Science, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037.
Pascal PoignardDepartment of Immunology and Microbial Science, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037 Department of Immunology and Microbial Science, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037 Department of Immunology and Microbial Science, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037.
Ron DiskinDepartment of Structural Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Pamela J BjorkmanDivision of Biology, California Institute of Technology, Pasadena, CA 91125 Howard Hughes Medical Institute, Chevy Chase, MD 20815.
Michael A EckhausDiagnostic and Research Services Branch, Office of the Director, National Institutes of Health, Bethesda, MD 20892.
Florian KleinLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065.
Hugo MouquetLaboratory of Humoral Response to Pathogens, Department of Immunology, Institut Pasteur, 75724 Paris, France.
Julio Cesar Cetrulo LorenziLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065.
Anna GazumyanLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065.
Dennis R BurtonDepartment of Immunology and Microbial Science, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037 Department of Immunology and Microbial Science, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037 Department of Immunology and Microbial Science, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037 Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Boston, MA 021142.
Michel C NussenzweigHoward Hughes Medical Institute, Chevy Chase, MD 20815 Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065.
Malcolm A MartinLaboratory of Molecular Microbiology, Virology Laboratory, Vaccine Research Center, and Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 malm@nih.gov ynishimura@niaid.nih.gov.
Yoshiaki NishimuraLaboratory of Molecular Microbiology, Virology Laboratory, Vaccine Research Center, and Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 malm@nih.gov ynishimura@niaid.nih.gov.
Rockefeller University · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USInstitut de Recherche Vaccinale · FRScripps Research Institute · USDuke Medical Center · USHoward Hughes Medical Institute · USInstitut Pasteur · FRInternational AIDS Vaccine Initiative · USLaboratory of Molecular Genetics · PLOffice of the Director · USWeizmann Institute of Science · IL

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
Molecular Biology Of Retroviruses Associated With AIDSZIAAI000415 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MARTIN, MALCOLM · 2009 to 2015
$11.3M
Intramural NIH HHSNIAID NIH HHS UM1 AI100663
6 · The paper itself

Abstract

It is widely appreciated that effective human vaccines directed against viral pathogens elicit neutralizing antibodies (NAbs). The passive transfer of anti-HIV-1 NAbs conferring sterilizing immunity to macaques has been used to determine the plasma neutralization titers, which must be present at the time of exposure, to prevent acquisition of SIV/HIV chimeric virus (SHIV) infections. We administered five recently isolated potent and broadly acting anti-HIV neutralizing monoclonal antibodies (mAbs) to rhesus macaques and challenged them intrarectally 24 h later with either of two different R5-tropic SHIVs. By combining the results obtained from 60 challenged animals, we determined that the protective neutralization titer in plasma preventing virus infection in 50% of the exposed monkeys was relatively modest (∼1:100) and potentially achievable by vaccination.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingDNA PrimersHIVHIV AntibodiesHumansLentivirus InfectionsMacaca mulattaMutagenesisNeutralization TestsRegression AnalysisSimian Immunodeficiency VirusVaccinationAntibodies, MonoclonalAntibodies, NeutralizingDNA PrimersHIV Antibodies

Identifiers

PMID25155019
PMCPMC4172223
OpenAlexW2171478268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.